1 National Institute of Food and Drug Safety Evaluation, "차세대염기서열분석(Next Generation Sequencing) 임상검사실 인증 검사분야별 가이드라인체세포(Somatic)"
2 Morgan GJ, "The genetic architecture of multiple myeloma" 12 : 335-348, 2012
3 Endrullat C, "Standardization and quality management in next-generation sequencing" 10 : 2-9, 2016
4 Palumbo A, "Revised International Staging System for Multiple Myeloma : A report from International Myeloma Working Group" 33 : 2863-2869, 2015
5 Merker JD, "Next-generation sequencing in hematologic malignancies: what will be the dividends?" 3 : 333-339, 2012
6 김혜진, "Korean Society for Genetic Diagnostics Guidelines for Validation of Next-Generation Sequencing-Based Somatic Variant Detection in Hematologic Malignancies" 대한진단검사의학회 39 (39): 515-523, 2019
7 Walker BA, "Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms" 28 : 384-390, 2014
8 Thomas M, "Integration of technical, bioinformatic, and variant assessment approaches in the validation of a targeted next-generation sequencing panel for myeloid malignancies" 141 : 759-775, 2017
9 김지훈, "Good Laboratory Standards for Clinical Next-Generation Sequencing Cancer Panel Tests" 대한병리학회 51 (51): 191-204, 2017
10 Papaemmanuil E, "Genomic classification and prognosis in acute myeloid leukemia" 374 : 2209-2221, 2016
1 National Institute of Food and Drug Safety Evaluation, "차세대염기서열분석(Next Generation Sequencing) 임상검사실 인증 검사분야별 가이드라인체세포(Somatic)"
2 Morgan GJ, "The genetic architecture of multiple myeloma" 12 : 335-348, 2012
3 Endrullat C, "Standardization and quality management in next-generation sequencing" 10 : 2-9, 2016
4 Palumbo A, "Revised International Staging System for Multiple Myeloma : A report from International Myeloma Working Group" 33 : 2863-2869, 2015
5 Merker JD, "Next-generation sequencing in hematologic malignancies: what will be the dividends?" 3 : 333-339, 2012
6 김혜진, "Korean Society for Genetic Diagnostics Guidelines for Validation of Next-Generation Sequencing-Based Somatic Variant Detection in Hematologic Malignancies" 대한진단검사의학회 39 (39): 515-523, 2019
7 Walker BA, "Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms" 28 : 384-390, 2014
8 Thomas M, "Integration of technical, bioinformatic, and variant assessment approaches in the validation of a targeted next-generation sequencing panel for myeloid malignancies" 141 : 759-775, 2017
9 김지훈, "Good Laboratory Standards for Clinical Next-Generation Sequencing Cancer Panel Tests" 대한병리학회 51 (51): 191-204, 2017
10 Papaemmanuil E, "Genomic classification and prognosis in acute myeloid leukemia" 374 : 2209-2221, 2016
11 Ley TJ, "Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia" 368 : 2059-2074, 2013
12 Feurstein S, "Genetic predisposition to leukemia and other hematologic malignancies" 43 : 598-608, 2016
13 Mrózek K, "Cytogenetics in acute leukemia" 18 : 115-136, 2004
14 Kim B, "Clinical evaluation of massively parallel RNA sequencing for detecting recurrent gene fusions in hematologic malignancies" 21 : 163-170, 2019
15 Papaemmanuil E, "Clinical and biological implications of driver mutations in myelodysplastic syndromes" 122 : 3616-3627, 2013
16 Gao P, "Challenges of providing concordant interpretation of somatic variants in non-small cell lung cancer : A multicenter study" 10 : 1814-1824, 2019
17 Bacher U, "Challenges in the introduction of next-generation sequencing(NGS)for diagnostics of myeloid malignancies into clinical routine use" 8 : 113-, 2018
18 Aguilera-Diaz A, "Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design" 15 : e0227986-, 2020